3 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 4 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
Follow Semaglutide Placebo: new trials by email Literature Review of Semaglutide Placebo trials Research Report on Semaglutide Placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes UBT251, UBT251 Placebo, Semaglutide - Diabetes Mellitus, Type 2 | Phase 2 | Recruiting | Novo Nordisk A/S | 300 | 2026-06-22 | 2026-10-07 |
| A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity NNC0662-0419, Semaglutide, NNC0662-0419 Placebo - Obesity | Phase 2 | Active not recruiting | Novo Nordisk A/S | 233 | 2026-06-09 | 2026-09-16 |
| Semaglutide Treatment in Type 1 Diabetes Semaglutide 2.4mg, Semaglutide placebo - Obesity in Diabetes, Obesity/Therapy | Phase 3 | Not yet recruiting | Nordsjaellands Hospital | 122 | 2025-10-01 | 2025-08-08 |
| COMMETS- Combination MCI Metabolic Syndrome Semaglutide, Intranasal insulin, Semaglutide placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 2 | Recruiting | Rutgers, The State University of New Jersey | 80 | 2024-01-30 | 2026-07-27 |
| Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes Semaglutide Pen Injector, Semaglutide placebo - Glucose Intolerance After a Recent History of Gestational Diabetes | Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 252 | 2023-09-14 | 2026-09-15 |
| Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) Semaglutide, Semaglutide Placebo - Overweight, Obesity | Phase 3 | Completed | Novo Nordisk A/S | 200 | 2023-05-30 | 2026-01-22 |
| Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH) NNC0194 0499 50 mg/mL, Placebo (NNC0194-0499), Semaglutide 3 mg/mL - Non-alcoholic Steatohepatitis | Phase 2 | Completed | Novo Nordisk A/S | 698 | 2021-08-31 | 2025-11-19 |
Obesity (3) · Diabetes Mellitus, Type 2 (2) · Alzheimer Disease (1) · Cognitive Dysfunction (1) · Dementia (1) · Diabetes Mellitus, Type 1 (1) · Diabetes, Gestational (1) · Insulin Resistance (1) · Metabolic Syndrome (1) · Non-alcoholic Fatty Liver Disease (1) · Overweight (1) · Weight Loss (1)
Novo Nordisk A/S (4) · Nordsjaellands Hospital (1) · Rutgers, The State University of New Jersey (1) · Universitaire Ziekenhuizen KU Leuven (1)
United States (3) · Australia (2) · Belgium (2) · Denmark (2) · Germany (2) · Poland (2) · Puerto Rico (2) · South Korea (2) · Spain (2) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · France (1) · Greece (1)
Tal Davidy (1) · Thomas F Dejgaard, MD, ph.d., endocrinologist (1)